Introduction
============

Compared with a nonfatal myocardial infarction, a nonfatal stroke causes a 1.5-fold greater loss of disability-adjusted life-year \[[@b1-jos-2015-01326]\]. Nonetheless, over the past decade there has been a clear and impressive decline in the incidence of stroke in several Western nations \[[@b2-jos-2015-01326]-[@b5-jos-2015-01326]\]. The positive change in the occurrence of stroke in these countries has been attributed primarily to better screening and treatment of established risk factors for stroke, particularly hypertension \[[@b6-jos-2015-01326]\]. The burden of stroke is greater in Asian countries than in the Western world, including a substantially higher incidence of stroke than myocardial infarction \[[@b7-jos-2015-01326]-[@b9-jos-2015-01326]\]. However, data on the extent to which several Asia countries have recently fared with regard to improvement in stroke outcomes are relatively sparse. One study suggested the incidence of stroke decreased from 1961 to 2000 in Japan \[[@b7-jos-2015-01326]\] and an overview study revealed that recurrent stroke decreased in each decade from 1960 to 2010 \[[@b10-jos-2015-01326]\]. Certainly more nationwide data on the evolving nature and trajectory of stroke in Asia are needed for research and planning purposes. The objective of this study was to explore risk factors, medication use, incidence, and one-year recurrence of stroke using the entire population in Taiwan by National Health Insurance Research Database (NHIRD).

Methods
=======

Study design and dataset
------------------------

We retrospectively assessed data collected 2000 through 2012, from Taiwan NHIRD. Taiwan has implemented a single-payer, compulsory National Health Insurance program in 1995, which includes reimburses of outpatient visits, hospital admissions, prescriptions for 99% of Taiwanese population. All contracted institutions must file claims according to standard formats, which are subsequently transformed into NHIRD.

Study population
----------------

We identified all hospitalized patients (≥ 18 years) who were admitted with a primary diagnosis of ischemic stroke (International Classification of Diseases, Ninth Revision codes 433, 434, 436) for the first time between 2000 and 2011. A prior study validating the diagnosis of acute ischemic stroke in National Health Insurance claims data using the Taiwan Stroke Registry as a reference revealed a positive predictive value of 88.4% and sensitivity of 97.3% \[[@b11-jos-2015-01326]\]. Another cross-sectional study showed that among confirmed cases of acute ischemic stroke in a hospital medical record, 94.5% were assigned 'ischemic stroke' as the principal diagnosis in the NHIRD \[[@b12-jos-2015-01326]\]. We only enrolled patients receiving brain computed tomography (CT) or magnetic resonance imaging (MRI) during hospitalization with the assumption that all patients with symptoms of acute stroke should receive brain imaging. This approach was intended to exclude stroke patients who were hospitalized for rehabilitation during chronic stage. Although brain imaging, especially CT, may not be able to reveal the cerebral infarction in patients with symptoms or signs of acute stroke, it can easily exclude intracranial hemorrhage. Thus NHIRD had a low probability of misclassifying hemorrhagic stroke into ischemic stroke if brain imaging was done.

The first-ever ischemic stroke during study period was defined as the index stroke. Patients were excluded if they had history of any strokes between 1997 and 1999. Patients were classified into three groups according to a year of stroke occurrence, which are 2000-2003, 2004-2007, and 2008-2011. This was a nationwide study that included all available and eligible patients.

Main outcome measures
---------------------

The primary outcome of this study was incidence of ischemic stroke in Taiwan. The incidence rate was defined as numbers of first-ever stroke patients each year divided by mid-year population per 100,000 population. The leading secondary outcome was the one-year stroke recurrent rate, defined as numbers of patients with first recurrent stroke (ischemic or hemorrhagic) within one year after index stroke divided by numbers of index stroke patients. The followed-up started from index stroke to stroke recurrence, or one year after index stroke, whichever came first.

Statistical analysis
--------------------

Baseline characteristics were presented as medians (interquartile ranges) for continuous variables and percentages for categorical variables, as appropriate. All statistics analyses were performed with SAS statistical software, version 9.2 (SAS Institute Inc., Cary, USA).

Results
=======

A total of 291,381 first-ever ischemic stroke patients were enrolled between 2000 and 2011. The average age was about 70 years and approximately 58.6% of them were men. The average length of hospital stay was about 7 days. More than half of patients had history of hypertension, which was from 59% to 63% and the frequency of hypertension in ischemic stroke was not much different in three time period. The frequencies of diabetes mellitus (from 29.6% to 34.0%) and hyperlipidemia (from 22.0% to 40.6%) increased steadily during study periods. Frequencies of atrial fibrillation (from 7.3% to 10.4%), chronic kidney disease (from 3.9% to 5.0%), and heart failure (from 7.3% to 9.3%) also increased during the study periods. The frequencies of brain CT use was decreased from 94.4% in 2000-2003 to 79.6% in 2008-2011 while brain MRI use was increased from 22.1% in 2000-2003 to 55.4% in 2008-2011. General characteristics are described in [Table 1](#t1-jos-2015-01326){ref-type="table"}. During the study periods, 30-day in--hospital mortality was from 1.7% to 1.9%.

About 37% of first-ever ischemic stroke patients received calcium channel blockers for antihypertension therapy during admission throughout the study period. The use of angiotensin receptor blockers was increased from 6% to 18.1% during the study periods. Frequencies of angiotensin-converting-enzyme inhibitors (16%) and diuretics (13%) were much the same among three time sections. The use of statin in ischemic stroke patients was increased from 8.8% in 2000-2003, 21.9% in 2004-2007, and to 30.8% in 2008-2011. Stroke patients received antiplatelet were 76.1% in 2000-2003, 85.3% in 2004-2007 and 86.6% in 2008-2011, respectively. There was 30.0% in 2000-2003, 28.9% in 2004-2007, and 34.5% in 2008-2011, respectively, of ischemic stroke patients with atrial fibrillation received oral anticoagulant agents during the hospitalization.

The incidence rate of ischemic stroke for people aged 18 years or older decreased gradually from 2000 (142.3 per 100,000 persons) to 2011 (129.5 per 100,000 persons) except there was an obvious drop in 2003 then increased in 2004 ([Figure 1](#f1-jos-2015-01326){ref-type="fig"}). One-year stroke recurrent rate decreased gradually which was 9.61% in 2000 and decreased to 7.27% in 2011 except there was an obvious drop in 2003 then increased in 2004 ([Figure 2](#f2-jos-2015-01326){ref-type="fig"}). Compare to women, men had a higher incident rate and recurrent rate of stroke. We suspected the Severe Acute Respiratory Syndrome, 14 March 2003 through 5 July 2003 in Taiwan, may cause decreasing rate of ischemic stroke hospitalization.

To explore the possible explanation for the drop of stroke incidence in 2003, we compared the stroke incidence in March through July from 2002 to 2004 and found that stroke incidence was substantially decreased in May and June, 2003, as compared to May and June in 2002 and 2004 ([Table 2](#t2-jos-2015-01326){ref-type="table"}).

Discussion
==========

This study provided an overview of baseline characteristics, risk factors, medication use during hospitalization, incidence, and one-year recurrence of first-ever ischemic stroke using the entire population of Taiwan from 2000 to 2011. Several findings, strengths and limitations merit discussion.

We used stroke hospitalization to represent incidence and recurrence of ischemic stroke with the assumption that all acute ischemic stroke patients should be hospitalized and the current health care system in Taiwan supports and encourages such a practice. However, a very small proportion of patients, likely those with minor stroke, may receive brain imaging at emergency departments or outpatient clinics but not be hospitalized due to various reasons, such as non-availability of beds or patients not wanting to wait. We found both incidence and recurrence of stroke dropped in May and June in 2003, which was during the fierce SARS epidemic in Taiwan. During that period of time, patients and medical doctors were less inclined to facilitate hospitalization unless the patient's condition was highly severe. Thus many patients with strokes of relatively minor severity may not have been counted in our analysis thereby potentially underestimating the real incidence and recurrence of ischemic stroke during that period of time.

Two studies exploring the incidence of stroke were conducted in 1980s \[[@b13-jos-2015-01326]\] and 1990s \[[@b14-jos-2015-01326]\], respectively, in certain communities in Taiwan. The annual incidence rate of stroke for people aged 36 years or older in a study, from 1986 to 1990, was 330 per 100,000 population \[[@b13-jos-2015-01326]\]. The other population-based stroke survey from 1993 to1996 reported that the annual incidence rate of stroke for people aged 50 years or older was 527 per 100,000 population \[[@b14-jos-2015-01326]\]. Since the current population was age 18 or older and we focused on incidence of ischemic stroke, as well as incidence of stroke was likely declining from 1986 to 2011, the annual incidence rate was lower in this study.

The characteristics of the stroke risk factors in this study is generally consistent with a large stroke registry from 2006 to 2008 but the rates of statin (30% vs. 38%) and antiplatelet (87% vs. 94%) use during hospitalization were somewhat lower in this study \[[@b15-jos-2015-01326]\]. While the current study included only first-ever ischemic stroke, the prior study \[[@b15-jos-2015-01326]\] also included 34% recurrent ischemic stroke patients, which may have led the treating medical doctors to adopt a more aggressive vascular risk reduction strategy. Also hospitals participating in a stroke registry are presumably highly motivated to improve care quality and may generally have more awareness of/interest in the use of evidence-based therapies for stroke risk reduction. We found mortality rate was lower in this study, as compared to the prior stroke registry study (1.9% vs. 4% \[[@b15-jos-2015-01326]\]) which is likely due to the fact that this study only enrolled first-ever ischemic stroke.

It is informative to compare the trends in stroke incidence, recurrence, and management of stroke in Taiwan with data from other Asian countries, such as Korea. Among hospital admissions with stroke as the primary diagnostic code during 2001 to 2009, hospitalizations for ischemic stroke increased substantially in Korea \[[@b16-jos-2015-01326]\]. This apparent rise in annual ischemic stroke incidence in Korea was likely due to an increase in the country's elderly population \[[@b16-jos-2015-01326]\]. However, the median age of the current study in Taiwan did not change during the study period. Moreover, a comparison of survey data obtained in 2002 vs. 1993-1996 showed a significant improvement in hypertension awareness, treatment, and control in Taiwan, which may have contributed to its declining incidence of ischemic stroke \[[@b17-jos-2015-01326]\]. Ischemic stroke incidence in the population aged 35-74 years was 226 per 100,000 person-years (including first-ever and recurrent ischemic stroke) in Korea 146 per 100,000 persons in our population aged 18 years or older (first-ever ischemic stroke only); while the annual rate of recurrent ischemic stroke was about 5.0% in Japan during 2007 to 2009 vs. a 7.7% annual recurrent stroke (ischemic or hemorrhagic) rate noted in Taiwan \[[@b18-jos-2015-01326]\].

In the Fukuoka ischemic stroke registry, mean age was 70 years, 76% had hypertension, 27% diabetes mellitus, 46% hyperlipidemia, and 26% atrial fibrillation \[[@b19-jos-2015-01326]\]. Our study had similar frequencies of stroke risk factors except only 10% patients had atrial fibrillation in this study. Since diagnosis of atrial fibrillation in hospitalized ischemic stroke patients typically relies on a single baseline 12-lead electrocardiogram or history of atrial fibrillation, it is conceivable that the frequency of paroxysmal atrial fibrillation in admitted ischemic stroke patients in Taiwan might be underestimated. Among ischemic stroke patients with atrial fibrillation in this study, 34% vs. 10% in a Chinese ischemic stroke registry \[[@b20-jos-2015-01326]\], received oral anticoagulants during hospitalization. The underuse of oral anticoagulant therapy in eligible Asian stroke patients during hospitalization may in part be due to concerns about hemorrhagic transformation. Also, 31% patients received statin therapy in this study at discharge vs. 35% in Fukuoka stroke registry, which is highly comparable \[[@b21-jos-2015-01326]\].

As compared to a prior study based on the control arms of clinical trials for secondary stroke prevention, the current study had higher recurrent rate of stroke (8% vs. 5% \[[@b10-jos-2015-01326]\]). The difference may exist in the prior study excluded patients with atrial fibrillation or severe carotid stenosis \[[@b10-jos-2015-01326]\] while this study included all first-ever ischemic stroke patients. Also, people participating in clinical trials may receive more rigorous risk factors control, which turns out to have lower recurrent stroke. Furthermore, the current study enrolled patients in the acute stage when the risk of recurrent stroke is high, whereas secondary stroke prevention trials, in general, enrolled patients after the acute stage. We found the one-year recurrent stroke was declining from 2000 to 2011, which may be explained by increasing use of statin (8.8% to 30.8%), antiplatelet agents (76.1% to 86.6%), and oral anticoagulant agents in atrial fibrillation (30.0% to 34.5%) during hospitalization among this period of time.

In addition to the limitations mentioned above, NHIRD does not provide information on a few established stroke risk factors, e.g. smoking and blood pressure levels during follow-up period. Also, we did not explore medication use at outpatient clinics after discharge from the first-ever ischemic stroke. Thus we could not explore the impact of these factors on the incidence and recurrence of stroke.

In conclusion, in accord with recent trends around the world \[[@b2-jos-2015-01326]-[@b5-jos-2015-01326]\], we observed that the annual incidence and one-year recurrence rates of stroke declined over the last decade in Taiwan. However, it would seem that the magnitude of reduction for incident stroke seen in Western nations of approximately 20% was much greater than the more modest 9% decrease noted in Taiwan. We observed a rise in the use of statins, antiplatelet agents, and oral anticoagulant agents for atrial fibrillation in Taiwan during this period of time, which probably contributed to the declining rate of stroke, but there appears to more room for improvement in risk factor control if Taiwan hopes to gain at least the same level of decrease in incident stroke observed in Western countries.
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###### 

Characteristic of hospitalized first-ever ischemic stroke patients from Taiwanese National Health Insurance Database (2000-2011), N=291,381

                                                                           Year 2000-2003, N = 92,525   Year 2004-2007, N = 95,681   Year 2008-2011, N = 94,543   *P* value
  ------------------------------------------------------------------------ ---------------------------- ---------------------------- ---------------------------- -----------
  Age (median, interquartile range \[IQR\])                                70 (61-77)                   69 (59-77)                   69 (59-78)                   0.0819
  Sex                                                                                                                                                             
   Male (%)                                                                57.2                         58.9                         59.5                         \< 0.0001
  Length of stay (day) (median, IQR)                                       7 (5-13)                     7 (5-14)                     7 (5-14)                     0.0939
  Computed tomography (CT) (%)                                             94.4                         85.1                         79.6                         \< 0.0001
  Magnetic resonance imaging (MRI) (%)                                     22.8                         38.0                         55.0                         \< 0.0001
  Medical history (%)                                                                                                                                             
   Hypertension                                                            58.9                         63.4                         62.5                         \< 0.0001
   Diabetes                                                                29.7                         33.1                         34.0                         \< 0.0001
   Hyperlipidemia                                                          22.0                         34.1                         40.7                         \< 0.0001
   Ischemic Heart Disease                                                  24.2                         28.9                         28.5                         \< 0.0001
   Atrial Fibrillation                                                     7.3                          8.9                          10.3                         \< 0.0001
   Chronic Kidney Disease                                                  4.0                          4.5                          5.0                          \< 0.0001
   Heart Failure                                                           7.3                          8.8                          9.4                          \< 0.0001
  30 day in--hospital mortality (%)                                        1.7                          1.6                          1.9                          \< 0.0001
  Medications                                                                                                                                                     
   Calcium channel blockers (CCBs)                                         36.6                         36.4                         36.3                         0.2651
   Angiotensin-converting-enzyme inhibitors (ACEIs)                        15.2                         18.0                         15.1                         0.826
   Angiotensin receptor blockers (ARBs)                                    6.2                          14.7                         18.6                         \< 0.0001
   Diuretics                                                               11.0                         13.5                         12.6                         \< 0.0001
   Statins                                                                 8.7                          21.7                         30.7                         \< 0.0001
   Antiplatelet agents                                                     75.7                         85.1                         86.3                         \< 0.0001
   Warfarin or novel oral anticoagulants (NOACs) for atrial fibrillation   29.8                         28.8                         34.2                         \< 0.0001

###### 

Crude stroke incidence rate from March to July between 2002 and 2004 (per 100,000 population)

  Year   Month                           
  ------ ------- ------- ------- ------- -------
  2002   12.94   12.96   12.52   11.70   12.53
  2003   12.83   11.54   9.27    9.91    12.19
  2004   12.91   11.54   12.13   12.36   11.81
